|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/506 | (2006.01) |
| A61K 31/506 | (2013.01) | ||
| A61K 31/551 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| C07D 279/12 | (2006.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 35/02 | (2006.01) |
| (11) | Number of the document | 3334432 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16835995.8 |
| Date of filing the European patent application | 2016-08-12 | |
| (97) | Date of publication of the European application | 2018-06-20 |
| (45) | Date of publication and mention of the grant of the patent | 2022-02-23 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/046862 |
| Date | 2016-08-12 |
| (87) | Number | WO 2017/027829 |
| Date | 2017-02-16 |
| (30) | Number | Date | Country code |
| 201562204400 P | 2015-08-12 | US | |
| 201662342711 P | 2016-05-27 | US |
| (72) |
COFFEY, Gregory , US
FENG, Jiajia , US
|
| (73) |
Portola Pharmaceuticals, Inc. ,
270 East Grand Avenue
Suite 22, South San Francisco, California 94080,
US
|
| (54) | CERDULATINIB FOR TREATING MYELOMA |
| CERDULATINIB FOR TREATING MYELOMA |